Peng H, Jabbari JS, Tian L, Wang C, You Y, Chua CC, Anstee NS, Amin N, Wei AH, Davidson N, Roberts AW, Huang D, Ritchie ME, Thijssen R. Single-cell Rapid Capture Hybridization sequencing to reliably detect isoform usage and coding mutations in targeted genes. Genome Research. 2025;:10.1101/gr.279322.124
Luo M-X, Tan T, Trussart M, Poch A, Nguyen TMH, Speed TP, Hicks DG, Bandala-Sanchez E, Peng H, Chappaz S, Slade C, Utzschneider DT, Koldej RM, Ritchie D, Strasser A, Thijssen R, Ritchie ME, Tam CS, Lindeman GJ, Huang DCS, Lew TE, Anderson MA, Roberts AW, Teh CE, Gray DHD. Venetoclax dose escalation rapidly activates a BAFF/BCL-2 survival axis in chronic lymphocytic leukemia. Blood. 2024;144(26):10.1182/blood.2024024341
Thiagarajah N, Dowling MR, Dunne K, Aarons D, Collins J, Tran S, Fleming S, Sutrave G, Hiwase D, Fong CY, Hsu B, Purtill D, Watson A-M, Kennedy GA, Stevenson WS, Larsen SR, Moore J, Perera T, Ritchie DS, Wei A, Roberts AW, Hamad N, Bajel A. Real-World Patterns of Care and Outcomes for Non-Favourable Risk Acute Myeloid Leukemia Treated with Intensive Chemotherapy across Australia and New Zealand- Data Linkage between the ALLG National Blood Cancer Registry (NBCR) and the Australia and New Zealand Transplant and Cellular Therapy (ANZTCT) Registry. Blood. 2024;144(Supplement 1):10.1182/blood-2024-209389
Loo S, Iland H, Tiong IS, Westerman D, Othman J, Marlton P, Chua CC, Purtill D, Rose H, Fleming S, Singhal D, Enjeti AK, Stevenson WS, Ng TF, Derek M, Vaughan L, Gasiorowski R, Ivey A, Souza A, Pattani R, Anstee NS, Koldej R, Ritchie DS, Loghavi S, Daver N, DiNardo CD, Roberts AW, Grove CS, Reynolds J, Wei AH. Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A- rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial. Blood. 2024;144(Supplement 1):10.1182/blood-2024-202895
D’Sa S, Dimopoulos MA, Jurczak W, Marlton P, Mulligan SP, Wahlin BE, Sobieraj-Teague M, Roberts AW, Tam CS, Castillo JJ, Allewelt H, Prathikanti R, Chan WY, Tian T, Schneider J, Vezan R, Opat SS. Long-term Clinical Outcomes in Patients with Waldenström Macroglobulinemia (WM) Who Received Zanubrutinib in the Phase 3 ASPEN Study: A Report from the Zanubrutinib Extension Study. Blood. 2024;144(Supplement 1):10.1182/blood-2024-199276
Gao M, Georgiou A, Lin VS, Jahja M, White CA, Anderson MA, McCormack MP, Roberts AW, Huang DCS, Thijssen R. Potential impact of NOTCH1 activation on venetoclax sensitivity in chronic lymphocytic Leukaemia: In vitro insights and clinical implications. British Journal of Haematology. 2024;205(4):10.1111/bjh.19604
Handunnetti SM, Anderson MA, Burbury K, Thompson PA, Burke G, Bressel M, Di Iulio J, Hicks RJ, Westerman D, Lade S, Pott C, Agarwal R, Koldej R, Ritchie D, Dreyling M, Dawson MA, Dawson S-J, Seymour JF, Roberts AW, Tam CS. Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions. Blood. 2024;144(8):10.1182/blood.2023023388
Diepstraten ST, Yuan Y, La Marca JE, Young S, Chang C, Whelan L, Ross AM, Fischer KC, Pomilio G, Morris R, Georgiou A, Litalien V, Brown FC, Roberts AW, Strasser A, Wei AH, Kelly GL. Putting the STING back into BH3-mimetic drugs for TP53-mutant blood cancers. Cancer Cell. 2024;42(5):10.1016/j.ccell.2024.04.004
Stilgenbauer S, Tausch E, Roberts AW, Davids MS, Eichhorst B, Hallek M, Hillmen P, Schneider C, Schetelig J, Böttcher S, Kater AP, Jiang Y, Boyer M, Popovic R, Ghanim MT, Moran M, Sinai WJ, Wang X, Mukherjee N, Chyla B, Wierda WG, Seymour JF. Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia. Blood Advances. 2024;8(8):10.1182/bloodadvances.2023011741
Lew TE, Bennett R, Lin VS, Whitechurch A, Handunnetti SM, Marlton P, Shen Y, Mulligan SP, Casan J, Blombery P, Tam CS, Roberts AW, Seymour JF, Thompson PA, Anderson MA. Venetoclax-rituximab is active in patients with BTKi-exposed CLL, but durable treatment-free remissions are uncommon. Blood Advances. 2024;8(6):10.1182/bloodadvances.2023011327
